<DOC>
	<DOCNO>NCT01540045</DOCNO>
	<brief_summary>One widely used treatment non-small cell lung cancer ( NSCLC ) combination paclitaxel-cisplatin . These drug may contribute taste alteration like dysgeusia . Which alters feed cancer patient , contribute anorexia , weight loss malnutrition , lead prognostic impact lower patient response chemotherapy , radiotherapy surgical treatment well increase toxic effect , impact treatment discontinuation therefore , morbidity survival patient . The objective study describe threshold perception recognition basic taste patient NSCLC treatment platin paclitaxel-based chemotherapy second cycle , analyze effect developement dysgeusia , well association nutritional status quality life .</brief_summary>
	<brief_title>Effect Chemotherapy With Paclitaxel/Cisplatin Development Dysgeusia Non Small Cell Lung Cancer</brief_title>
	<detailed_description>Lung cancer lead cause death malignancy country . It recently report induce 11.5 % cancer death Mexico , rate 6.5 per 100 000 people . Non-Small Cell Lung Cancer ( NSCLC ) account 80 % lung cancer case . Less 20 % resectable disease National Cancer Institute Mexico exclusively less 2 % , represent chemotherapy standard care patient . One widely use drug combination paclitaxel-cisplatin . It report prevalence malnutrition 60 79 % type cancer , major contributor morbidity mortality . The etiology reside systemic effect tumor toxic effect treatment low level hematologic , nausea , vomit , mucositis , anorexia , dysgeusia , among others . Weight loss strong impact response chemotherapy , radiotherapy surgery , well increase toxic effect impact discontinuation treatment consider independent predictor survival patient NSCLC . Is estimate 20 % cancer patient cause death inanition effect . Among frequent symptom advance unresectable cancer treatment may affect food intake hence nutritional status , early satiety dysgeusia ( 61 % 46 % respectively ) . As difficult change early satiety , dysgeusia field select strategy management . The dysgeusia define change taste manifest distortion taste , lack taste ( ageusia ) , decreased sensitivity perception ( hypogeusia ) increase sensitivity flavor ( hypergeusia ) . The development dysgeusia clinical significance etiology cancer anorexia affect eat habit contribute weight loss malnutrition consequently affect quality life . The chemotherapy may contribute dysgeusia . It report prevalence 56.3 % Dysgeusia cancer patient type treatment . As well , zinc deficiency associate hypogeusia , metal involve various level physiology role taste various level cell several organization . Several study link consumption dysgeusia energy macronutrients , weight loss , lack appetite early satiety . The type tumor , stage , chemotherapy regimen serum zinc level associate dysgeusia , exact mechanism underlining disturbance know totality . No known chemotherapy present dysgeusia . In addition study area methodological weakness , among include heterogeneous population ( patient diagnosis malignancy breast , lung , prostate , multiple myeloma lymphoma ) , different pattern treatment ( different chemotherapy drug , radiotherapy schedule combination form measurement dysgeusia , besides absence dysgeusia baseline evaluation chemotherapy establish causal association chemotherapy taste alteration . Also , unknown dysgeusia impact body composition determine bioelectrical impedance , phase angle consumption micronutrient ( iron , sodium , zinc , B6 , B12 ) . That 's necessary continue study phenomenon develop well understanding nature , frequency , severity duration dysgeusia patient advance lung cancer , role zinc exert development impact consumption food , anthropometric parameter quality life patient chemotherapy regimen chemotherapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Dysgeusia</mesh_term>
	<mesh_term>Taste Disorders</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients 18 year old INCan histopathological diagnosis Lung Cancer Stage III IV ECOG score â‰¤ 2 Candidates firstline chemotherapy base 1 st Paclitaxel / cisplatin 200 mg/m2 75 every 3 week Signed informed consent ( ethical scientific committee No . ( 010/023 ( IMO ) ( CB/618 Patients withdraw consent want continue evaluation study Common cold hay fever , recent dental procedure , evidence gingival inflammation infection oral mucosa People diagnose epilepsy neurological disorder associate Concomitant radiotherapy head neck .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Dysgeusia</keyword>
	<keyword>Antineoplastic Combined Chemotherapy Protocols</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Cisplatin</keyword>
</DOC>